<PAGE> 1
---------------------------
OMB APPROVAL
---------------------------
OMB Number: 3235-0145
Expires: August 31, 1991
Estimated average burden
hours per response....14.90
---------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D - FORM
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
Ergo Science Corporation
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $0.01 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
29481E-10-6
--------------------------------------------------------------------------------
(CUSIP Number)
Thomas R. Hurtekant, c/o 1445 Ross Avenue, 20th Floor, Dallas, Texas 75202-2785;
214/978-8907
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
August 30, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Section 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box [ ].
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
SCHEDULE 13D - FORM
---------------------- -----------------
CUSIP NO. 29481-E-10-6 PAGE 1 OF 4 PAGES
---------------------- -----------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
Steuben Investment Company, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
Not applicable.
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF ---------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH ---------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 0
---------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!SCHEDULE 13D - FORM
<PAGE> 3
---------------------- -----------------
CUSIP NO. 29481-E-10-6 PAGE 2 OF 4 PAGES
---------------------- -----------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
Hunt Financial Corporation
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
Not applicable.
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF ---------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH ---------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 0
---------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 4
SCHEDULE 13D - FORM
---------------------- -----------------
CUSIP NO. 29481-E-10-6 PAGE 3 OF 4 PAGES
---------------------- -----------------
ITEM 1: SECURITY AND ISSUER.
This statement on Schedule 13D relates to the Common Stock, par value
$0.01 per share ("Common Stock"), of Ergo Science Corporation, a Delaware
corporation (the "Company").
The principal executive offices of the Company are located at 43 High
Street, North Andover, Massachusetts 01845.
ITEM 2: IDENTITY AND BACKGROUND.
Hunt Financial Corporation and Steuben Investment Company, L.P. are
respectively a Delaware corporation and a Delaware partnership engaged in
general investment business. Their principal offices are each at 1445 Ross
Avenue, 20th Floor, Dallas, Texas 75202. During the last five years, neither of
such entities, nor any of their officers, directors or principal owners has been
convicted in a criminal proceeding or has been a party to a civil proceeding of
a judicial or administrative body which resulted in or subjected them to a
judgment decree or final order enjoining future violations of federal or state
securities laws, prohibiting or mandating activities subject to federal or state
securities laws or finding a violation of any such laws.
ITEM 3: SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
The transaction reported is a sale of the reporting persons' entire
position in Ergo Science Corporation so the question is inapplicable.
ITEM 4: PURPOSE OF TRANSACTION
The transaction reported was a sale of the reporting persons' entire
interest in Ergo Science.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
On September 6, 2000, the reporting persons sold their entire interest
in Ergo Science Corporation in a private transaction to Court Square Capital
Limited for $1.60 cash per share (See Exhibit A) and ceased to be beneficial
owners of five percent of a class of securities of that issuer. No other
transactions have been effected in the last sixty days by the reporting persons.
ITEM 6: CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER
Not applicable.
ITEM 7: MATERIAL TO BE FILED AS EXHIBITS
Exhibit A. Stock Purchase Agreement
<PAGE> 5
SCHEDULE 13D - FORM
---------------------- -----------------
CUSIP NO. 29481-E-10-6 PAGE 4 OF 4 PAGES
---------------------- -----------------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Hunt Financial Corporation
10-3-2000 By: /s/ THOMAS R. HURTEKANT
------------- ------------------------------------------
(Date) Thomas R. Hurtekant, Vice President
Steuben Investment Company, L.P.
10-3-2000 By: /s/ RAY L. HUNT
------------- ------------------------------------------
(Date) Ray L. Hunt, Managing General Partner
Initials: TRH
<PAGE> 6
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
------- -----------
<S> <C>
Exhibit A. Stock Purchase Agreement
</TABLE>
